

LYMPHOID NEOPLASIA

Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL

Mateusz Antoszewski,^{1,2} Nadine Fournier,¹⁻³ Gustavo A. Ruiz Buendía,³ Joao Lourenco,³ Yuanlong Liu,^{2,4,5} Tara Sugrue,^{1,2,6} Christelle Dubey,^{1,2,7} Marianne Nkosi,^{1,2} Colin E. J. Pritchard,⁸ Ivo J. Huijbers,^{8,9} Gabriela C. Segat,¹⁰ Sandra Alonso-Moreno,¹¹ Elisabeth Serracanta,¹¹ Laura Belver,^{11,12} Adolfo A. Ferrando,¹³ Giovanni Ciriello,^{2,4,5} Andrew P. Weng,¹⁰ Ute Koch,^{1,2} and Freddy Radtke^{1,2}

¹Ecole Polytechnique Fédérale de Lausanne (EPFL), School of Life Sciences, Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, Switzerland; ²Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland; ³Bioinformatics Core Facility, Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland; ⁴Department of Computational Biology, University of Lausanne (UNIL), Lausanne, Switzerland; ⁵Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland; ⁶Botnar Research Centre for Child Health, University of Basel & ETH Zürich, Basel, Switzerland; ⁷INSELSPITAL, Universitätsspital Bern, Universitätsklinik für Thoraxchirurgie, Forschungsabteilung Thoraxchirurgie, Bern, Switzerland; ⁸Mouse Clinic for Cancer & Aging (MCCA)/Transgenic Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ⁹Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands; ¹⁰Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada; ¹¹Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain; ¹²Catalan Institute of Oncology-Immuno Procure, Barcelona, Spain; and ¹³Institute for Cancer Genetics, Columbia University Medical Center, New York, NY

KEY POINTS

- Tcf1 shapes a Notch1-induced T-ALL-prone chromatin landscape in early hematopoietic progenitors.
- Tcf1 orchestrates chromatin accessibility within the Notch1-regulated Myc super-enhancer.

NOTCH1 is a well-established lineage specifier for T cells and among the most frequently mutated genes throughout all subclasses of T cell acute lymphoblastic leukemia (T-ALL). How oncogenic NOTCH1 signaling launches a leukemia-prone chromatin landscape during T-ALL initiation is unknown. Here we demonstrate an essential role for the high-mobility-group transcription factor Tcf1 in orchestrating chromatin accessibility and topology, allowing aberrant Notch1 signaling to convey its oncogenic function. Although essential, Tcf1 is not sufficient to initiate leukemia. The formation of a leukemia-prone epigenetic landscape at the distal Notch1-regulated Myc enhancer, which is fundamental to this disease, is Tcf1-dependent and occurs within the earliest progenitor stage even before cells adopt a T lymphocyte or leukemic fate. Moreover, we discovered a unique evolutionarily conserved Tcf1-regulated enhancer element in the distal Myc-enhancer, which is important for the transition of preleukemic cells to full-blown disease.

Introduction

Signaling events governing cell identity, differentiation, and proliferation converge on spatial folding of chromatin, eliciting programs essential for all cellular functions.¹ Thus, the adoption of the appropriate genome architecture is imperative for development and tissue homeostasis. Dysregulation of chromatin topology, as a consequence of genomic alterations or mutations affecting chromatin regulatory proteins, has functionally been linked to cancer.²⁻⁵ Nevertheless, how lineage-specifying transcription factors establish a cancer-permissive chromatin landscape is not well understood. The Notch signaling pathway regulates many cell fate decisions during development and homeostasis and is dysregulated in cancer.⁶⁻⁸ In the hematopoietic system, Notch1 is an essential specifier of the T cell lineage^{9,10} and is one of the most frequently mutated genes in T cell acute lymphoblastic leukemia (T-ALL).^{11,12} Activating *NOTCH1* mutations occur in many subclasses of T-ALL, and the growth of these cancers often remains *NOTCH1*-dependent.^{13,14} Aberrant *NOTCH* signaling has been associated with the regulation of enhancers in T-ALL,¹⁵ in particular with activation of the proto-oncogene *MYC* through a distal enhancer

located ~1.5 Mb downstream of its promoter.^{16,17} Mechanisms by which aberrant Notch establishes a leukemia-prone chromatin landscape are currently unknown.

Tcf1 harbors a histone deacetylase domain¹⁸ and has been shown to be an important epigenetic regulator during multiple stages of T cell development (TCD).^{19,20} In T-ALL, canonical Wnt signaling, mediated through β -catenin/Tcf1, has been shown to be active in a subpopulation of cells enriched for leukemia-initiating cells. Importantly, genetic inactivation of β -catenin reduced leukemia initiation frequency in Notch1-driven T-ALL.²¹

Here we assessed the function of the Notch1 target gene *Tcf7*, which encodes for Tcf1,^{22,23} and the canonical Wnt mediator β -catenin for their coordinate role with oncogenic Notch1 to induce T-ALL. In this context, the transcriptome and the epigenome were analyzed using ATAC-seq, ChIP-seq, and in situ Hi-C. Analysis of hematopoietic progenitors allowed us to gain novel insights into the formation of chromatin topology at T-ALL initiation. Finally, we assessed the leukemia-prone landscape of the Notch1-regulated *Myc* enhancer region for conserved regulatory elements.




Figure 1.

Methods

Mice

Gt(ROSA)26Sor^{tm1(Notch1)Dam}/J (*N1IC^{lox/lox}*), *Notch1^{lox/lox}*, *B6.129-Ctnnb1^{tm2Kem}/KwJ* (β -catenin^{lox/lox}), and *Mx1Cre* mouse lines have been described.^{9,24-26} Additional information on compound lines, the conditional *Tcf7* and the *TMe* mouse lines, are described in supplemental Information.

Flow cytometry and cell sorting

LSKs were defined as CD45.2⁺ lineage-negative CD117⁺ Sca1⁺eGFP⁺. For ATAC-seq, RNA-seq, ChIP-seq, and Hi-C analyses, oncogenic Notch1-expressing LSKs were sorted using a FACSAria (Becton Dickinson) or MoFlo Astrios EQ (Beckman Coulter). Oncogenic NOTCH1-expressing human cord blood (CB) cells used for ATAC-seq were defined as CD45⁺ CD34⁺CD38⁺CD5⁺CD7⁺eGFP⁺ and sorted using a FACSAria. Sorting and analysis strategies are outlined in supplemental Information. The purity of sorted subsets was >97%. Flow-cytometric data were acquired on a Gallios (Beckman Coulter) and analyzed using FlowJo v10.7.0. Primary and secondary antibodies are listed in supplemental Table 2.

Ethics statement

All animal work was carried out in accordance with Swiss national guidelines. This study (VD1099) was reviewed and approved by the cantonal veterinary service.

Results

Tcf7 is essential for Notch1-mediated T-ALL induction

We generated a conditional gene-targeted mouse line for the *Tcf7* gene to investigate the function of Tcf1 in the context of Notch1-driven T-ALL. Due to the importance of Notch1⁹ and Tcf1^{22,27} in T cell fate specification, we analyzed 6- to 8-week-old age-matched *Tcf7^{Δ/Δ} Mx1Cre* and *Notch1^{Δ/Δ} Mx1Cre* animals. As expected, gene inactivation of either *Notch1* or *Tcf7* resulted in impaired TCD (supplemental Figure 1A-H), confirming the validity of the conditional *Tcf7* loss-of-function (LoF) alleles. Interestingly, *Tcf7^{Δ/Δ} Mx1Cre* mice did not develop T cell lymphoma within the investigated time frame as previously reported for *Tcf7^{-/-}* and *Tcf7^{Δ/Δ} Vav-Cre* animals,^{28,29} which may be explained by the different developmental stages at which *Tcf7* is inactivated.

Confirming the importance of both genes in TCD, we assessed the function of Tcf1 in the context of Notch1-driven T-ALL. The *R26 N1IC^{lox/+} Mx1Cre* genetic Notch1 gain-of-function (GoF) mouse model was used to induce leukemogenesis²⁶ in bone marrow (BM) chimeras. *Mx1Cre*-mediated recombination results

in the expression of a dominant active form of *Notch1* (*N1IC*) linked to an eGFP reporter driven from the *Rosa26* locus.²⁶ *N1IC^{lox/+} Tcf7^{lox/lox} Mx1Cre* compound animals were used to interrogate LoF of *Tcf7* in oncogenic Notch1-driven T-ALL (Figure 1A). Activation of the *Mx1Cre* recombinase drove the inactivation of *Tcf7*, leading to loss of Tcf1 protein (supplemental Figure 1I).

Expression of *N1IC* resulted in T-ALL development (Figure 1B). Flow cytometric analysis of *N1IC* GoF chimeric BM cells revealed an accumulation of CD4⁺CD8⁺ double-positive (DP) and CD8⁺ single-positive leukemic cells (Figure 1C), with concomitant loss of hematopoietic lineages including erythroblasts, B cells, and myeloid cells (Figure 1D).

Surprisingly, none of the *N1IC Tcf7^{Δ/Δ}* BM chimeras developed disease (Figure 1B). Importantly, abrogation of T-ALL in *N1IC Tcf7^{Δ/Δ}* BM chimeras was not a mere consequence of loss of the transplant (supplemental Figure 1J). However, erythroblasts, myeloid cells, immature B220⁺IgM⁻ B cell progenitors, and to a somewhat lesser extent, mature B220⁺IgM⁺ B cells were efficiently suppressed (Figure 1D). To determine a potential role of β -catenin-mediated canonical Wnt signaling in Notch1-driven T-ALL, we performed β -catenin LoF studies in an oncogenic Notch1 GoF background, in which *N1IC* is expressed from both *Rosa26* alleles. Again, no disease was observed in *N1IC^{Δ/Δ} Tcf7^{Δ/Δ}* chimeras, whereas all *N1IC^{Δ/Δ} β -catenin^{Δ/Δ}* BM chimeras succumbed to T-ALL, albeit with a short-term kinetic delay compared with *N1IC^{Δ/Δ}* chimeras (Figure 1E-G; supplemental Figure 1I).

These results demonstrate that Tcf1 exerts essential, β -catenin-independent functions in Notch1-driven T-ALL initiation, while suppression of other hematopoietic lineages imposed by forced Notch signaling appears to be largely Tcf1-independent.

Oncogenic Notch1 requires Tcf1 to induce a T cell-specific gene expression program in early hematopoietic progenitors

Mx1Cre-mediated recombinase activity has been previously demonstrated in all blood lineages, including hematopoietic stem cells.³⁰ *Mx1Cre*-mediated *N1IC* expression occurs in hematopoietic progenitors, including LSKs within the different chimeric cohorts. As *Tcf7* gene inactivation profoundly affects *N1IC*-driven T-ALL induction, we aimed to investigate early changes during disease onset. Thus, we performed RNA-seq on sorted LSK BM progenitors from Controls (*N1IC^{lox/+} Tcf7^{lox/lox}*), *Tcf7^{Δ/Δ}*, *N1IC*, and *N1IC Tcf7^{Δ/Δ}* chimeras 72 hours post*Mx1Cre*-mediated recombination (Figure 2A). Analysis of differential gene expression revealed no major differences between Controls and *Tcf7^{Δ/Δ}* LSKs, indicating that ablation of *Tcf7* alone had no major

Figure 1. Initiation of Notch1-driven T-ALL is *Tcf7*-dependent. (A) Schematic representation of BM chimeras transplanted with the indicated genotypes: *R26 N1IC^{lox/+}* or *R26 N1IC^{lox/+} Tcf7^{lox/lox}* (Controls, gray), *R26 N1IC^{lox/+} Mx1Cre* (*N1IC*, red), or *R26 N1IC^{lox/+} Tcf7^{lox/lox} Mx1Cre* (*N1IC Tcf7^{lox/lox}*, blue) and treatment schedule. (B) Kaplan-Meier survival plot of chimeras after last poly(I:C) injection. *N1IC* mice (n = 8), *N1IC Tcf7^{Δ/Δ}* (n = 10), and Controls (n = 7) followed for 199 days. Log-rank (Mantel-Cox) test, ****P value < .0001. (C-D) Phenotypic flow cytometric analysis of transplanted (CD45.2⁺) and induced (eGFP⁺ for *N1IC* and *N1IC Tcf7^{Δ/Δ}*) BM cells from Controls (n = 4), *N1IC* (n = 6), and *N1IC Tcf7^{Δ/Δ}* (n = 5). Quantification of absolute numbers is shown for T cells, erythroid cells, myeloid cells, and B cells. Data are represented as mean \pm standard error of the mean (SEM). Unpaired t-test, *P value < .05; **P value < .01; ***P value < .001; ****P value < .0001. (E) Schematic representation of BM chimeras with Controls (gray, n = 3), *R26 N1IC^{lox/lox} Mx1Cre* (*N1IC^{Δ/Δ}*, red, n = 18), *R26 N1IC^{lox/lox} Tcf7^{lox/lox} Mx1Cre* (*N1IC^{Δ/Δ} Tcf7^{Δ/Δ}*, blue, n = 15), and *R26 N1IC^{lox/lox} β -catenin^{lox/lox} Mx1Cre* (*N1IC^{Δ/Δ} β -catenin^{Δ/Δ}*, light green, n = 9) mice. (F) Kaplan-Meier survival analysis of transplanted mice after last poly(I:C) injection and followed for 115 days. Log-rank (Mantel-Cox) test, ***P value < .001; ****P value < .0001. (G) Phenotypic flow cytometric analysis of transplanted (CD45.2⁺) and induced (eGFP⁺ for *N1IC^{Δ/Δ}*, *N1IC^{Δ/Δ} Tcf7^{Δ/Δ}*, and *N1IC^{Δ/Δ} β -catenin^{Δ/Δ}*) BM. Panels on the left depict representative plots of CD4 and CD8 T cells with quantification of absolute numbers on the right. Data are represented as mean \pm SEM. Unpaired t-test, ****P value < .0001.




Figure 2.

impact on gene expression (Figure 2B; supplemental Figure 2A). In contrast, the expression of leukemogenic *N11C* led to profound reprogramming of the cellular transcriptome. We identified 414 and 423 genes significantly down- and upregulated, respectively, in *N11C*-expressing LSKs compared with Controls (Figure 2B; supplemental Figure 2A). Among the 423 upregulated genes, 119 were *Tcf1*-dependent as they were lost in the LSK population of *N11C Tcf7 $\Delta\Delta$* chimeras. Interestingly, analysis of the gene ontology biological processes of the *Tcf7*-dependent upregulated genes in LSKs derived from *N11C* chimeras revealed an association with lymphocyte differentiation/activation and included T cell activation and differentiation (Figure 2B-C; supplemental Figure 2B). Quantitative analysis confirmed the upregulation of T cell-specific transcripts, including *Tcf7*, *Il2ra*, *Gata3*, and *CD3e* in *N11C*-expressing LSKs. In contrast, *N11C* was unable to upregulate T cell-specific genes in the absence of *Tcf1* (Figure 2D), albeit that Notch target genes such as *Notch1* itself and *Hes1* were upregulated by *N11C*, independently of *Tcf1* (Figure 2E-F).

Next, we tested whether *Tcf7* GoF in Notch1-proficient BM progenitors would be sufficient to induce ectopic TCD and/or T-ALL. Thus, we performed *Tcf7* GoF experiments using *Tcf7* IRES eGFP-expressing BM chimeras. Analysis of *Tcf7* GoF chimeras 13 weeks posttransplantation revealed neither ectopic TCD nor T-ALL induction compared with Controls or retrovirally-driven *N11C* BM chimeras analyzed at endpoint (supplemental Figure 2C-F).

Altogether, this demonstrates that *Tcf1* is essential for *N11C* to elicit a T cell-specific gene expression program. However, *Tcf1* alone in vivo is not sufficient to induce a T cell program with leukemic self-renewal activity even in a Notch1-proficient background.

Tcf1 regulates chromatin accessibility in *N11C*-expressing LSKs

As *Tcf1* has been associated with epigenetic regulation of TCD,^{18,20} we asked whether *Tcf1* is necessary to modulate chromatin accessibility enabling forced *N11C* to permit a leukemia-specific program in hematopoietic progenitors. Thus, we performed ATAC-seq on LSKs derived from Controls, *Tcf7 $\Delta\Delta$* , *N11C*, and *N11C Tcf7 $\Delta\Delta$* chimeras (Figure 3A). Differential accessibility analysis showed pronounced modulation of the epigenome in response to *N11C* and *Tcf1* (Figure 3B; supplemental Figure 3A). Genes in proximity to *N11C*-induced *Tcf1*-dependent chromatin modulation were predominantly associated with T cell differentiation, proliferation, and activation (Figure 3C; supplemental Figure 3B). Indeed, *N11C*-driven chromatin accessibility at the promoter and putative enhancer regions of T cell-specific genes, including *Ptcrx* and *Cd3e*, were *Tcf1*-dependent (Figure 3D).

Lineage determination of early hematopoietic progenitors is governed by specific master transcription factors (TFs) and their controlled binding to regulatory chromatin loci.^{31,32} To assess whether such regulation in T-ALL initiation is dependent on *N11C*- and *Tcf1*-mediated chromatin modulation, we performed TF footprint and TF binding sites (BSs) analysis of gained and lost ATAC-seq peaks. The top differential accessible BSs identified were *Runx*, *Tcf1*, *Lef1*, and *RBPJ* in both *N11C*-expressing vs Controls and *N11C* vs *N11C Tcf7 $\Delta\Delta$* settings. These findings confirmed that chromatin loci are open for these TFs in a Notch1- and *Tcf1*-regulated manner. Gain of *Gata* TF BSs as a consequence of *Tcf7* deficiency in *N11C* vs *N11C Tcf7 $\Delta\Delta$* footprint analysis indicates that in an *N11C* GoF context, their repression is *Tcf1*-dependent. In contrast, *Cebp* and *Pax5* TF BSs correlate with negative differential binding scores independent of *Tcf7* (Figure 3E-F; supplemental Figure 3C-D).

These results suggest that forced *N11C* expression in LSKs modulates a chromatin landscape that allows induction of T cell-specific genes, and this process appears to be *Tcf1*-dependent. Contrarily, oncogenic *N11C* simultaneously closes chromatin loci that would be permissive for induction of alternative cell fates such as myeloid, B- or erythroid-cell lineages. These processes are regulated by *Tcf7*-dependent and -independent mechanisms.

Dynamic large-scale genomic interactions promoting leukemogenesis rely on Notch1 and *Tcf1*

Using chromatin accessibility analysis, we identified an early involvement of *Tcf1* and Notch1 in the events of T-ALL commitment from hematopoietic progenitors. It is not clear whether 3D genome folding is equally affected, hence impacting cell fate decisions in oncogenic processes.¹ We thus performed in situ Hi-C, allowing for spatial profiling of all genomic loci at once³³ on LSKs derived from *N11C*, *N11C Tcf7 $\Delta\Delta$* , and control chimeras (Figure 4A). Data resolution of 2.5 kb³⁴ and improved quality over recently published in situ Hi-C on hematopoietic stem cells³⁵ allowed us to proceed confidently with the analysis of topology (Figure 4B; supplemental Figure 4A-D).

Genomic compartment A regions contain open, active chromatin, while B compartments are correlated with heterochromatin.^{36,37} While large genomic regions of A and B compartments remain relatively stable, fine-grained subcompartments analysis can reveal subtle compartment changes.^{33,38} Direct analysis of subcompartment switching between *N11C* vs Controls, *N11C Tcf7 $\Delta\Delta$* vs *N11C*, and *N11C Tcf7 $\Delta\Delta$* vs Controls LSKs revealed high genome stability (65% to 70% stability). However, the proportion of the subcompartment changes, irrespectively of genotypes and comparison, varied between 12% and 15% (Figure 4C-D; supplemental Figure 4E). Interestingly, subcompartment rank switching correlated with transcription changes of differentially expressed genes after

Figure 2. *Tcf7* regulates the expression of genetic T cell signature in BM progenitors in response to oncogenic Notch1. (A) Experimental setup: induced CD45.2⁺ BM cells from Controls (black, n = 3), *Tcf7 $\Delta\Delta$* (light blue, n = 3), *N11C* (red, n = 3), or *N11C Tcf7 $\Delta\Delta$* (blue, n = 3) mice were FACS purified for lineage⁺, cKit⁺ (CD117⁺), and Sca1⁺ BM progenitors (LSK) for RNA-seq analysis. Representative flow cytometric plots are shown. (B) Heatmap depicting regulated genes in *N11C* vs Controls (FDR < 0.05, $-1.5 > FC > 2$) from gene ontology (GO) T cell activation collection, shown for all experimental groups. (C) Enrichment of biological pathways from GO biological process (GOBP) collection in genes with induced expression by *N11C* and *Tcf7* from RNA-seq on LSK cells. Top 20 pathways are shown. *P* values were calculated with Fisher's exact test. (D) Expression of investigated genes measured as TPM (transcripts per kilobase million) with induced expression by *N11C* and *Tcf7* from RNA-seq on LSK cells. Barplots from left to right of each graph: Controls, *Tcf7 $\Delta\Delta$* , *N11C*, and *N11C Tcf7 $\Delta\Delta$* . Data are represented as mean \pm standard error of the mean (SEM). One-way ANOVA, **P* value < .05; ***P* value < .01; ****P* value < .001. (E) Enrichment of biological pathways from GOBP collection in genes with induced expression by *N11C* and independent of *Tcf7* from RNA-seq on LSK cells. Top 20 pathways are shown. *P* values were calculated with Fisher's exact test. (F) Expression of investigated genes measured as TPM with induced expression by *N11C* and independent of *Tcf7* from RNA-seq on LSK cells. Barplots from left to right of each graph: Controls, *Tcf7 $\Delta\Delta$* , *N11C*, and *N11C Tcf7 $\Delta\Delta$* . Data are represented as mean \pm SEM. One-way ANOVA, ***P* value < .01; ****P* value < .001.




Figure 3.

integration of our RNA-seq data comparing *N11C* vs Controls and *N11C Tcf7 Δ/Δ* vs Controls. No significant correlations were obtained when comparing *N11C Tcf7 Δ/Δ* vs *N11C* (Figure 4C-D; supplemental Figure 4E). A specific example of a Notch1-induced and *Tcf7*-dependent gene, whose expression was directly correlated with subcompartment switching (*N11C* vs Controls and *N11C Tcf7 Δ/Δ* vs *N11C*), is *Tspan9³⁹* (Figure 4E; supplemental Figure 4F).

We next identified topologically associating domains (TADs) from contact matrices at 10 kb resolution. Since boundaries of TADs are known to be enriched for CTCF,^{33,40} we performed CTCF analysis using ChIP-seq on sorted LSKs from Controls, *N11C*, and *N11C Tcf7 Δ/Δ* . Enrichment analysis at both TAD anchors identified oriented binding of CTCF at over 37% of chromatin domains (supplemental Figure 5A). Thus, only these domains were taken into consideration for subsequent analyses. To quantify modulations of TADs between conditions, we performed an analysis of TAD boundary changes. Forty-five TAD boundaries were increasing with overexpression of *N11C*. These were found to be *Tcf1*-dependent as their score decreased in *N11C Tcf7 Δ/Δ* LSKs (Figure 4F). On the contrary, 52 TAD boundaries had a decreased score and were *Tcf1*-dependent in *N11C* LSKs (Figure 4F). The majority of TAD boundaries were classified as nondifferential, and only around 2.5% to 3% were categorized as increased in strength in different genetic comparisons (Figure 4F-G). Genes proximal to dynamic TAD boundaries revealed no genome-wide significant correlation between gene expression and TAD boundary changes (supplemental Figure 5B). *Grp2* has been identified as an example among differentially expressed genes due to Notch1- and *Tcf1*-dependent changes in TAD boundaries (Figure 4H; supplemental Figure 5C-E).^{41,42}

Our analysis revealed fine-tuned coordination by *N11C* and *Tcf7* cooperatively orchestrate distinctive higher-order genomic folding during leukemic fate programming.

Establishment of EPIs in T-ALL initiation partly depends on *Tcf1*

After assessing the effects of Notch1 and *Tcf1* on high-order genome organization, we focused on 3D chromatin loop interactions established in *N11C* and *N11C Tcf7 Δ/Δ* . Local chromatin interactions are of importance when connecting regulatory regions (RRs), such as promoters with distal enhancers, leading to modulated gene expression.⁴³ Identified interactions were established and compared between Controls, *N11C*, and *N11C Tcf7 Δ/Δ* genotypes to determine both genotype-specific and shared enhancer-promoter interactions (EPIs) (Figure 5A).

Since not all identified chromatin loops connect genes with potential RRs, we focused on those with confirmed proximity to transcription start sites (TSS) at one of the anchors. Investigation of chromatin loops with differential expression dependent on

both Notch1 and *Tcf1* revealed genes from leukemic ontology associated with T-ALL, such as *Pdgfrb* (Figure 5B; supplemental Figure 6A).⁶ Although the investigation of Notch1-dependent but *Tcf1*-independent chromatin loops in *N11C Tcf7 Δ/Δ* identified leukemic ontology as being highly enriched, the affected genes cannot be considered T-ALL-related, rather they have been described in myeloid malignancies (supplemental Figure 6B-C).⁴⁴ Moreover, analysis of data for genome-wide correlation within dynamic condition-specific chromatin loops revealed no significant differences (Figure 5C).

Regulation of gene expression in T-ALL by NOTCH1 has been linked to distal enhancers, where NOTCH1 occupancy correlates with increased levels of H3K27ac.¹⁵ Thus, LSKs from Controls, *N11C*, and *N11C Tcf7 Δ/Δ* chimeras were isolated for genome-wide H3K27acChIP-seq analysis (Figure 5D). We investigated whether identified chromatin loops were connecting active RRs in Notch1- or *Tcf1*-dependency by profiling H3K27ac at non-TSS loop anchors. Interestingly, the highest genome-wide acetylation levels of connected chromatin loci were detected in *N11C*-specific loops, highlighting the importance of *Tcf1* in such distal activation downstream of Notch1 signaling (Figure 5E). Subsequently, all genes controlled by Notch1 and *Tcf1* were examined for the involvement of distal regulatory elements. We performed unbiased genome-wide analysis for Notch1- and *Tcf1*-dependent EPIs correlated with differential gene expression. We identified up to 239 differential EPIs, of which 147 correlated with a respective increase or decrease in gene expression (Figure 5F; supplemental Figure 6D-F). Dynamic EPIs were analyzed with respect to dynamic subcompartments. Increased EPI strength positively correlated with increasing compartment ranks across analyzed comparisons (supplemental Figure 6G-I). Direct comparison of differential EPI between experimental chimeras revealed that ontologies related to lymphocyte and T cell activation were significantly enriched in *N11C* (Figure 5G). Expression of *Bcl11b⁴⁵* and *Gpr174⁴⁶* are 2 examples of genes regulated by differential EPI being Notch- and *Tcf1*-dependent (Figure 5H-I; supplemental Figure 6J-K).

Taken together, 3D chromatin interactions in T-ALL-prone LSKs are regulated by *Tcf1* in order to calibrate the transcriptional output of genes during Notch1-mediated transformation processes.

A novel *Tcf1*-regulated *Myc*-enhancer region is essential for Notch1-driven T-ALL progression

A conserved *Notch1 MYC enhancer (NMe)* located 1.5 Mb downstream of the *MYC* promoter drives transformation and T-ALL.¹⁶ Notch1-Rbpj BSs are located in a broad super-enhancer region that directly interacts with the *MYC* promoter via long-range chromatin looping.¹⁷ Genetic deletion of the *NMe* impairs T-ALL development.¹⁶ We investigated whether the *NMe* and *Myc* gene/promoters are regulated in a *Tcf7*-

Figure 3. Notch1 and *Tcf1* epigenetically establish T-lineage specification in early BM progenitors. (A) Induced CD45.2⁺ BM cells from Controls (black, n = 3), *Tcf7 Δ/Δ* (light blue, n = 3), *N11C* (red, n = 3), or *N11C Tcf7 Δ/Δ* (blue, n = 3) mice were FACS purified for lineage⁺, cKit⁺ (CD117), and Sca1⁺ BM progenitors (LSK) for ATAC-seq analysis. Characteristic flow cytometric plots are shown. (B) Heatmap depicting all regulated genomic loci in comparison *N11C* vs Controls and then used as a reference and compared with *N11C Tcf7 Δ/Δ* (FDR < 0.01) for ATAC-seq called and centered peaks, shown for all experimental groups. Color scale for centered values is shown below the heatmap. (C) Enrichment of biological pathways from gene ontology biological process (GOBP) collection in genes with induced proximal accessibility by *N11C* and *Tcf7*. Top 20 pathways are shown from ontologies with a fold enrichment >2 and FDR < 0.05. *P* values were calculated with Fisher's exact test. (D) Integrative genomics viewer chromatin accessibility profiles for all experimental groups are shown at the promoter of *Ptcr α* and for *Cd3e*. Tracks were group-scaled. Schematic representation of genetic loci is depicted below the profiles. (E-F) Footprint analysis for transcription factors binding regulated by (E) *N11C* vs Controls and (F) *N11C* vs *N11C Tcf7 Δ/Δ* .




Figure 4. Notch1 and Tcf1 regulate 3D organization of chromatin compartments and domains. (A) Induced CD45.2⁺ BM cells from Controls (black, n = 2), *N1IC* (red, n = 2), or *N1IC Tcf7 $\Delta\Delta$* (blue, n = 2) mice were FACS purified for lineage⁻, cKit⁺ (CD117), and Sca1⁺ BM progenitors (LSK) and processed for in situ Hi-C analysis. Characteristic flow cytometric plots are shown. (B) Juicebox-generated contact matrices from chromosome 15: whole chromosome, at 250 kb resolution




Figure 4 (continued) (far left); 50 kb resolution (middle left); chromatin domains at 10 kb resolution (middle right); chromatin loops (blue squares) at highest resolution of 2.5 kb (far right) shown for Controls. The 1D regions corresponding to a contact matrix are indicated in the diagrams below and right. The intensity of each pixel represents the normalized number of contacts between a pair of loci. Maximum intensity: 1350, 293, 20, 3 (from left to right). (C-D) Chromatin subcompartment switching between (C) Controls vs *N1IC* and (D) *N1IC Tcf7 Δ/Δ* vs *N1IC* (left panels). X-axis indicates the number and direction of subcompartments switching: stable (0), toward active (+), and toward inactive (-). Association with gene expression differences (FDR < 0.1) for genes within dynamic compartments is shown in right panels. Unpaired Wilcoxon test, *****P* value < .0001. (E) IGV CCCTC-Binding Factor (CTCF), chromatin accessibility, and H3K27ac profiles for all experimental groups shown for *Tspan9*. Tracks were group-scaled. Schematic representation of genetic loci is depicted below the profiles. Compartment tracks identified by Calder are shown at the bottom for all experimental conditions. (F) Quantitative comparison of identified TAD boundary changes differential, nondifferential, and shifted (nonoverlapping) in comparison *N1IC* vs Controls and *N1IC* vs *N1IC Tcf7 Δ/Δ* . (G) Proportion of TAD boundary changes classified into 5 categories for all comparisons as indicated. (H) Schematic depiction of Notch1- and Tcf1-dependent TAD regulating the expression of *Grap2* gene. Hi-C matrix at 10 kb resolution is shown on top, TopDom and TADCompare analyzed TAD with differential boundary is shown below (highlighted in red) together with boundary score visualization. IGV profiles for CTCF and ATAC-seq are shown for *N1IC* LSKs. Tracks were group-scaled. Representation of genetic loci is depicted below the tracks.

dependent manner during the early initiation phase of T-ALL in *N1IC*-expressing LSKs. While chromatin accessibility at the *Myc* promoter was not significantly different, accessibility at the *NMe* site was *Tcf7*-dependent (Figure 6A; supplemental

Table 3). However, in *N1IC*-expressing LSKs, gene expression and enhancer-promoter looping of *Myc* itself were not differentially upregulated at this early stage (supplemental Figure 7A-B).




Figure 5. Chromatin looping and activation status of regulatory elements are Notch1- and Tcf1-dependent. (A) Three-way quantitative comparison of identified chromatin loops for condition-specific and shared loops for Controls, *N11C*, and *N11C Tcf7 $\Delta\Delta$* . (B) Overrepresentation analysis (ORA) for *N11C*-specific loop-associated genes for phenotype catalog. Top 10 pathways are shown. *P* values were calculated with Fisher's exact test. (C) Association of gene expression differences




Figure 5 (continued) (adjusted P value $\leq .05$) for genes within dynamic condition-specific loops (from panel A). Left and right panels show \log_2 fold-change for condition-specific loop-associated genes from RNA-seq analysis. (D) Induced CD45.2⁺ BM cells from Controls (black, $n = 3$), *N11C* (red, $n = 3$), or *N11C Tcf7 $\Delta\Delta$* (blue, $n = 3$) mice were FACS purified for lineage⁻, cKit⁺ (CD117), and Sca1⁺ BM progenitors (LSK) for histone mark ChIP-seq analysis with H3K27ac antibody. (E) H3K27ac ChIP-seq signal at the non-TSS loop anchor. Shown at 5 kb windows around the center of a peak or loop anchor. Enrichment for H3K27ac is scaled. Quantification of the global signal for non-TSS loop anchors is depicted on the right. Data are shown from left to right for Controls, *N11C*, and *N11C Tcf7 $\Delta\Delta$* . (F) Gene-annotated scatterplot for differential EPI (x-axis) for differentially expressed genes (\log_2FC , y-axis) in comparison *N11C* vs Controls. Dots for genes with differential EPI >1 are shown in red. (G) ORA for genes with differential EPI in comparison *N11C* vs Controls for gene ontology biological processes (GOBP) catalog. Top 20 pathways are shown. P values were calculated with Fisher's exact test. (H) Expression of *Bcl11b* measured as transcripts per million (TPM) from RNA-seq on LSK cells. Data are represented as mean \pm standard error of the mean. One-way ANOVA, *** P value $< .001$. (I) Representation of 5 kb interacting regions between the indicated genomic coordinates color-coded based on their EPI strength value (top). Identified enhancer (gray line) and promoter (yellow line) interaction is enlarged in the top left corner. Integrative genomics viewer CTCF, chromatin accessibility, and H3K27ac profiles are shown for all experimental conditions (bottom). Tracks were group-scaled. Schematic representation of genetic loci is depicted below the profiles.

Unexpectedly, analysis of chromatin accessibility revealed a prominent regulatory site 14 kb downstream of the *NMe* regulated by Notch1 in a Tcf1-dependent manner. We named this newly discovered region *TMe* (Tcf1-regulated Myc enhancer) (Figure 6A; supplemental Table 3). Attributing functional relevance to this novel *TMe*, we hypothesized that *cis*-acting elements within this accessible chromatin region would be conserved between different species, similarly to the *NMe*.⁴⁷ Phylogenetic footprint analysis of *TMe* across vertebrates revealed multiple highly conserved regulatory elements (Figure 6B). The high conservation of this cluster of TF BSs in placental mammals is indicative of a functional role for the *TMe* region. Hence, we assessed the ability of forced NOTCH1 expression to establish an oncogenic chromatin landscape in human hematopoietic progenitor cells. We used a system that models NOTCH1-mediated T-ALL in vitro through lentiviral transduction of human CB cells.⁴⁸ Specifically, oncogenic NOTCH1 was expressed in CD34⁺ cells and analyzed by ATAC-seq (Figure 6C). Gene Ontology analysis revealed that NOTCH1-regulated chromatin modulation is associated with immune response-activating cell surface receptor signaling, T cell receptor (TCR) signaling, leukocyte activation, and others (Figure 6D). Taking advantage of footprint analysis, we identified TCF1 as a regulator of ontologies such as TCR signaling and pathways in cancer. Moreover, forced *NOTCH1* expression induced chromatin accessibility in T cell genes, such as *IL2RA*, and, although statistically not significant, accessibility of the *TMe* region increased and resulted in TCF1 expression (Figure 6E-G; supplemental Table 4) in CD34⁺ cells. *TMe* is also accessible in NOTCH1-dependent DND-41 T-ALL cells (supplemental Figure 7C). This indicates that not only are DNA sequences conserved between mammals but that Notch-mediated chromatin accessibility gain is also conserved between mice and humans. Furthermore, ChIP and reverse ChIP analysis using murine and human T-ALL cell lines indicated that Tcf1 binds to both *NMe* and *TMe* (Figure 7A; supplemental Figure 7D-E).

We thus hypothesized that Tcf1 orchestrates Notch1-induced chromatin organization in the distal *Myc*-enhancer through binding to *NMe* and/or *TMe*. To test the putative function of the *TMe* region in the context of Notch1-driven T-ALL, we generated CRISPR-targeted mice for *TMe* and established *R26 N11C^{lox/+} TMe^{+/-Mx1Cre}* and *R26 N11C^{lox/+} TMe^{-/-Mx1Cre}* compound lines. *TMe^{-/-}* mice are fertile, viable, and exhibit normal hematopoietic development (supplemental Figure 8). The consequences of *TMe* deletion in the context of Notch-driven T-ALL were assessed in BM chimeras. The effect of *TMe* genomic deletion on epigenetic features was addressed by ATAC-seq on LSKs of *N11C* and *N11C TMe^{-/-}* mice. As expected, chromatin accessibility was readily detectable for both *NMe* and *TMe* regions in *N11C*-derived LSKs, while only the *NMe* region retained chromatin accessibility in *N11C TMe^{-/-}* chimeras (Figure 7B).

Strikingly, analysis of leukemogenesis revealed that none of the *N11C TMe^{-/-}* chimeras developed T-ALL and only 40% of *N11C TMe^{+/-}* succumbed, while chimerism was stable over time on all genetic backgrounds (Figure 7C-E). Flow cytometric analysis of BM cells at midstage disease of *N11C* and endpoint of *N11C TMe^{+/-}* and *N11C TMe^{-/-}* chimeras revealed similar proportions of ectopic CD4⁺CD8⁺ DP preleukemic cells in all compound chimeras (Figure 7F). While preleukemic cells in *N11C* BM chimeras progressed from a *Myc*-negative DP stage to *Myc*-expressing CD8⁺ leukemic cells, surprisingly efficient progression to aggressive leukemia is impaired in the majority of *N11C TMe^{+/-}* and in all *N11C TMe^{-/-}* chimeras (Figure 7F-G). Accordingly, comparable *Myc* expression was observed between *N11C* and *N11C TMe^{+/-}* chimeras that developed T-ALL (Figure 7H). Moreover, 3C analysis showed that *NMe* interacts with the *Myc* promoter in sorted *Myc*-expressing *N11C* CD8⁺ T-ALL cells. Interaction is reduced in *Myc*-negative *N11C* DP and even more so in *N11C TMe^{-/-}* DP cells (Figure 7G,I),




Figure 6. *Tcf1* exerts a crucial regulatory function within distal *Myc* enhancers. (A) Integrative genomics viewer (IGV) profiles for Controls, *N1IC*, and *N1IC Tcf7 $\Delta\Delta$* from ATAC-seq analysis performed on sorted murine LSKs for *Myc* promoter (left panel), *NMe* (red), and *TMe* (green) (right panel). Tracks were group-scaled. Schematic representation of genetic loci is depicted below the profiles. (B) *TMe* evolutionary conservation tree (left panel) and predicted ultraconserved transcription factor binding motifs in the




Figure 6 (continued) *TMe* sequence (right panel). PhastCons conservation scores are indicated above the sites (score >0.5). (C) Schematic representation of lentiviral (LV) overexpression experiment using CD34⁺ human CB cells transduced with LV overexpressing *NOTCH1* (red, n = 2). Cells were used for ATAC-seq analysis. ATAC-seq (GSM4743251 and GSM4743252) data sets from CD34⁺ human CB cells were used as Controls. (D) Enrichment of biological pathways from GO biological process collection in genes with induced proximal accessibility by human *NOTCH1* and Controls CD34⁺ human CB cells. Top 10 pathways are shown from ontologies with an FDR ≤ 0.01. P values were calculated with Fisher's exact test. (E) TOBIAS footprint analysis *NOTCH1* vs Controls. Pathway enrichment analysis from KEGG pathway catalog regulated by TCF1-confirmed footprint. Top 5 pathways are shown with corresponding FDR. The panel below represents IGV chromatin accessibility profiles for both experimental groups shown for *IL2RA*. Tracks were group-scaled; scaling is shown in the top left corner. Schematic representation of genetic loci is depicted below the profiles together with footprint analysis at TCF1-binding motif. (F) IGV chromatin accessibility profiles for *TMe* in human *NOTCH1* and Controls CD34⁺ human CB cells. Tracks were group-scaled. (G) Flow cytometric-based analysis of intracellular TCF1 levels in *NOTCH1* (red) and Controls (gray) CD34⁺ human CB cells.

raising the possibility that *TMe* is important for efficient *Myc* promoter-enhancer interaction during disease progression.

Discussion

We discovered an essential function of Tcf1 in orchestrating chromatin accessibility allowing aberrant Notch1 signaling to execute its tumorigenic function in T-ALL. *Tcf7* has been shown to be a direct target gene of Notch1 in TCD^{22,23} and implicated in the regulation of TCD.^{19,20} This function of Tcf1 has been shown to be independent of canonical Wnt signaling.^{49,51} Similarly, our results show that β-catenin is dispensable in Notch1-induced T-ALL. Nonetheless, β-catenin deficiency resulted in a delayed T-ALL progression, which is in agreement with previous observations that canonical Wnt signaling is active in a subpopulation of leukemia-initiating cells.²¹

β-catenin-independent functions of Tcf1 during TCD have been linked to its ability to function as an epigenetic regulator. Tcf1 with Lef1 establish the CD8 T cell-lineage by repressing CD4-lineage-associated genes via histone deacetylase activity.¹⁸ Overexpression of Tcf1 in fibroblasts or progenitors in vitro can regulate T cell-specific genes.^{20,22,23} Thus, we assessed whether Tcf1 in vivo is sufficient to mimic oncogenic Notch1. Retroviral overexpression of Tcf1 in hematopoietic progenitors was insufficient to induce ectopic TCD or T-ALL in vivo, even in a Notch1-proficient background. In *N11C*-expressing LSKs, however, ex vivo epigenetic and gene expression profiling revealed that Tcf1 is essential

to modulate chromatin accessibility and allows Notch1-driven expression of T cell-specific and growth-promoting genes. Without Tcf1, the chromatin structure of promoters and enhancers of T cell-specific genes such as *CD3ε*, *Ptcrα*, and the distal *Myc* enhancer are not accessible despite oncogenic Notch expression. Thus, Notch1-induced, Tcf1-dependent regulation of chromatin accessibility appears to be an early key event in T-ALL induction. This Tcf1-specific function is in agreement with the previously established role of Tcf1 during normal TCD.^{20,22}

Lineage specification requires not only the expression of distinct genes but also simultaneous repression of other lineage programs.⁵² Our ATAC-seq footprint analyses reveal that forced *N11C* expression in LSKs induces repression of master regulators of other blood lineages such as *Cebps*, *Pax5*, and *Gatas*. Thus, Tcf1 contributes to proper lineage specification independently of the gene expression of such master regulators.

Regulation of leukemogenesis in BM progenitors is governed by chromatin accessibility of regulatory elements proximal to genes, as assessed by ATAC-seq, as well as by distal chromatin interactions established through EPIs. Genome-wide identification of the 3D landscape revealed fine-tuned control of T-ALL-associated genes. Dynamic chromatin subcompartments, TADs, and loops directly affect the genes reported in clinical T-ALL.^{39,53} However, we found that dynamics of genome folding are much more subtle than changes observed during cellular differentiation.⁵⁴ Importantly, Tcf1 is essential for such an




Figure 7. TMe enhancer site is essential for T-ALL initiation. (A) ChIP-qPCR analysis for Tcf1 binding in murine T-ALL (mT-ALL, n = 3), wild type LSKs (Neg Ctrl, n = 3) and IgG Controls (n = 2) at NMe (each left bar, red) and TMe (each right bar, green). Data are represented as mean \pm standard error of the mean (SEM). (B) Genomic localization of TMe in mm10, depicting the strategy for deletion of genomic element. Integrative genomics viewer profiles for N11C (top, red, n = 3) and N11C TMe^{-/-} (bottom, green, n = 3) showing chromatin accessibility from ATAC-seq analysis on sorted LSKs. Tracks were group-scaled, scaling is shown in the top left corner. (C) Schematic representation of BM chimeras R26 N11C^{lox/+} Mx1Cre (N11C), R26 N11C^{lox/+} TMe^{+/-} Mx1Cre (N11C TMe^{+/-}), and R26 N11C^{lox/+} TMe^{-/-} Mx1Cre (N11C TMe^{-/-}) mice. (D) Kaplan-Meier survival analysis of transplanted mice after last poly(I:C) injection. N11C mice (red, n = 8), N11C TMe^{+/-} (orange, n = 10), and N11C TMe^{-/-} (green, n = 11) were followed for 341 days post poly(I:C) injection. Log-rank (Mantel-Cox) test, *P value < .05; ***P value < .001; ****P value < .0001. (E) Relative percentages of CD45.2⁺ transplanted cells in peripheral blood of N11C mice (red, n = 12), N11C TMe^{+/-} (orange, n = 11), and N11C TMe^{-/-} (green, n = 12), post poly(I:C) injection. Timepoints are indicated below the graph. Data are represented as mean \pm SEM. (F) Flow cytometric-based phenotypic analysis of transplanted (CD45.2⁺) and induced (eGFP⁺) BM cells. Plots depict representative profiles from N11C mouse T-ALL midstage progression (red), N11C TMe^{+/-} at the endpoint (orange), and N11C TMe^{-/-} at the endpoint (green). (G) Total protein analysis by western blot for Myc, Tcf1, and β -actin on FACS purified T cells from BM of experimental groups: N11C CD8⁺ (n = 2), N11C DP (CD4⁺CD8⁺, n = 2), N11C TMe^{+/-} DP (CD4⁺CD8⁺, n = 4), and N11C TMe^{-/-} DP (CD4⁺CD8⁺, n = 2), as indicated. (H) Total protein analysis by western blot for Myc and β -actin on FACS purified T cell blasts from BM of experimental groups: N11C CD8⁺ (n = 3) and N11C TMe^{+/-} CD8⁺ (n = 3), as indicated. (I) 3C-qPCR analysis for interactions between Myc promoter and NMe on FACS purified T cells from BM of experimental groups: N11C CD8⁺ (n = 3), N11C DP (n = 3), N11C TMe^{-/-} DP (n = 3). Bacterial artificial chromosome (BAC) clones spanning the region of interest were used as negative groups. Data are represented as mean \pm SEM. Unpaired t-test, *P value < .05.

organization of chromatin topology and activation of specific regulatory elements in Notch1-initiated leukemogenesis.

NOTCH1 has been shown to regulate the *MYC* oncogene through the *NMe*¹⁷ in T-ALL. Although *Myc* is not differentially expressed in Controls, *N1IC* and *N1IC Tcf7^{ΔΔ}* LSKs, our epigenetic analyses revealed that accessibility of *NMe* is already established early in *N1IC*-expressing LSKs in a *Tcf1*-dependent manner. In the absence of *Tcf1*, forced *N1IC*-expression cannot render *NMe* accessible. Thus, the chromatin landscape is already shaped for future events when cells express appropriate TFs and/or additional chromatin regulators. We identified an additional evolutionarily conserved *TMe* region 14 kb downstream of *NMe* and tested its functional importance. We hypothesized that *TMe* is important to establish chromatin accessibility of *NMe*. However, genomic deletion of *TMe* revealed that *NMe* accessibility could still be established in LSKs of *N1IC TMe*^{-/-} chimeras. ChIP-qPCR analysis identified direct regulation of *NMe* by bound *Tcf1*. Whereas *NMe*-deficient mice develop marked thymic atrophy characterized by severe reduction of DP thymocytes,¹⁶ *TMe*^{-/-} mice revealed that *TMe* is dispensable for physiological TCD. Strikingly, in T-ALL initiation, none of the *N1IC TMe*^{-/-} chimeras developed T-ALL and only 40% of *N1IC TMe*^{+/-} succumbed to disease. *N1IC TMe*^{-/-} chimeras developed preleukemic DP T cells but did not progress to lethal disease. These preleukemic DP cells did not express detectable levels of *Myc*, suggesting that *TMe* is required for expression and upregulation of *Myc* and thus disease progression. The conceptual framework of our study can help to identify additional regulators of the preleukemic to leukemic transition of relevance to therapeutic approaches.

Acknowledgments

The authors would like to acknowledge the staff from the Flow Cytometry Facility at the University of Lausanne for their excellent technical support and thank the technical staff from the CPG of EPFL.

This work was in part supported by the Swiss National Science Foundation (SNF 31003A_1467198 and SNF 310030_188505), the Swiss Cancer League, and the US National Institutes of Health NIH grants P30 CA013696 and R35 CA210065.

Authorship

Contribution: F.R. and U.K. provided conceptualization; M.A., T.S., U.K., C.E.J.P., I.J.H., and A.P.W. provided methodology; N.F., G.A.R.B., J.L.,

and Y.L. provided software analysis; M.A., T.S., M.N., C.D., U.K., N.F., G.A.R.B., J.L., Y.L., G.C.S., S.A.-M., and E.S. provided formal analysis and investigation; C.E.J.P., I.J.H., G.C.S., A.P.W., L.B., and G.C. provided resources; F.R., M.A., and U.K. wrote the original draft; F.R., M.A., U.K., G.A.R.B., J.L., Y.L., L.B., A.A.F., G.C., and A.P.W. reviewed and edited the manuscript; M.A., U.K., and F.R. provided visualization; F.R. and U.K. provided supervision; U.K. and M.A. provided project administration; and F.R. handled funding acquisition.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: M.A., 0000-0002-7651-0547; N.F., 0000-0002-9347-7929; G.A.R.B., 0000-0002-4935-1480; J.L., 0000-0001-6549-5209; Y.L., 0000-0002-2483-024X; T.S., 0000-0001-6132-113X; M.N., 0000-0003-2522-8370; C.E.J.P., 0000-0001-7848-9377; I.J.H., 0000-0002-7954-8604; G.C.S., 0000-0002-9161-079X; S.A.-M., 0000-0001-6670-085X; E.S., 0000-0002-0167-1215; L.B., 0000-0001-7493-7072; A.A.F., 0000-0002-6212-8574; G.C., 0000-0003-2021-8683; A.P.W., 0000-0001-7394-5425; U.K., 0000-0001-7914-7061; F.R., 0000-0003-4315-4045.

Correspondence: Freddy Radtke, Ecole Polytechnique Fédérale de Lausanne (EPFL), Swiss Institute for Experimental Cancer Research (ISREC), Station 19, CH-1015 Lausanne, Switzerland; e-mail: freddy.radtke@epfl.ch; and Ute Koch, Ecole Polytechnique Fédérale de Lausanne (EPFL), Swiss Institute for Experimental Cancer Research (ISREC), Station 19, CH-1015 Lausanne, Switzerland; e-mail: ute.koch@epfl.ch.

Footnotes

Submitted 18 May 2021; accepted 22 December 2021; prepublished online on *Blood* First Edition 12 January 2022. DOI 10.1182/blood.2021012077.

Detailed bioinformatics tools used for the analysis of highthroughput data are provided in supplements. ATAC-seq, RNAseq, ChIP-seq, and Hi-C data sets of murine LSK and human ATAC-seq were deposited (GSE169121). Publicly available ATAC-seq (GSM4743251 and GSM4743252) datasets from noninfected and noncultured CD34+ human CB cells were used as Controls. Publicly available ATAC-seq (GSM5259037) dataset on DND-41 was analyzed as well.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

REFERENCES

1. Stadhouders R, Filion GJ, Graf T. Transcription factors and 3D genome conformation in cell-fate decisions. *Nature*. 2019;569(7756):345-354.
2. Flavahan WA, Drier Y, Liao BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. *Nature*. 2016;529(7584):110-114.
3. Katainen R, Dave K, Pitkänen E, et al. CTCF/cohesin-binding sites are frequently mutated in cancer. *Nat Genet*. 2015;47(7):818-821.
4. Hnisz D, Weintraub AS, Day DS, et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. *Science*. 2016;351(6280):1454-1458.
5. Jiang S. Tet2 at the interface between cancer and immunity. *Commun Biol*. 2020; 3(1):667.
6. Heilmann AM, Schrock AB, He J, et al. Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia. *Leukemia*. 2017;31(9):1989-1992.
7. Morrow MA, Mayer EW, Perez CA, Adlam M, Siu G. Overexpression of the Helix-Loop-Helix protein Id2 blocks T cell development at multiple stages. *Mol Immunol*. 1999;36(8): 491-503.
8. Richter-Pechařna P, Kunz JB, Hof J, et al. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. *Blood Cancer J*. 2017;7(2):e523.
9. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. *Immunity*. 1999;10(5):547-558.
10. Wilson A, MacDonald HR, Radtke F. Notch 1-deficient common lymphoid precursors adopt a B cell fate in the thymus. *J Exp Med*. 2001;194(7):1003-1012.
11. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science*. 2004;306(5694):269-271.
12. Ma X, Liu Y, Liu Y, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature*. 2018;555(7696):371-376.

13. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. *Annu Rev Pathol.* 2008;3(1):587-613.
14. Koch U, Radtke F. Notch in T-ALL: new players in a complex disease. *Trends Immunol.* 2011;32(9):434-442.
15. Wang H, Zang C, Taing L, et al. NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. *Proc Natl Acad Sci USA.* 2014;111(2):705-710.
16. Herranz D, Ambesi-Impiombato A, Palomero T, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nat Med.* 2014;20(10):1130-1137.
17. Yashiro-Ohtani Y, Wang H, Zang C, et al. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. *Proc Natl Acad Sci USA.* 2014; 111(46):E4946-E4953.
18. Xing S, Li F, Zeng Z, et al. Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity. *Nat Immunol.* 2016;17(6):695-703.
19. Raghu D, Xue H-H, Mielke LA. Control of lymphocyte fate, infection, and tumor immunity by TCF-1. *Trends Immunol.* 2019; 40(12):1149-1162.
20. Johnson JL, Georgakilas G, Petrovic J, et al. Lineage-determining transcription factor TCF-1 initiates the epigenetic identity of T cells. *Immunity.* 2018;48(2):243-257.e10.
21. Giambra V, Jenkins CE, Lam SH, et al. Leukemia stem cells in T-ALL require active Hif1 α and Wnt signaling. *Blood.* 2015; 125(25):3917-3927.
22. Weber BN, Chi AW-S, Chavez A, et al. A critical role for TCF-1 in T-lineage specification and differentiation. *Nature.* 2011; 476(7358):63-68.
23. Germar K, Dose M, Konstantinou T, et al. T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling. *Proc Natl Acad Sci USA.* 2011;108(50):20060-20065.
24. Brault V, Moore R, Kutsch S, et al. Inactivation of the β -catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. *Development.* 2001;128(8): 1253-1264.
25. Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. *Science.* 1995;269(5229):1427-1429.
26. Murtaugh LC, Stanger BZ, Kwan KM, Melton DA. Notch signaling controls multiple steps of pancreatic differentiation. *Proc Natl Acad Sci USA.* 2003;100(25):14920-14925.
27. Verbeek S, Izon D, Hofhuis F, et al. An HMG-box-containing T-cell factor required for thymocyte differentiation. *Nature.* 1995; 374(6517):70-74.
28. Yu S, Zhou X, Steinke FC, et al. The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy [published correction appears in *Immunity.* 2014;40(1):166]. *Immunity.* 2012;37(5):813-826.
29. Wang F, Qi Z, Yao Y, et al. Exploring the stage-specific roles of Tcf-1 in T cell development and malignancy at single-cell resolution. *Cell Mol Immunol.* 2021;18(3):644-659.
30. Gudmundsson KO, Oakley K, Han Y, Du Y. Analyzing gene function in adult long-term hematopoietic stem cells using the interferon inducible Mx1-Cre mouse system. *Methods Mol Biol.* 2014;1194:313-325.
31. Iwasaki H, Mizuno S, Arinobu Y, et al. The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. *Genes Dev.* 2006; 20(21):3010-3021.
32. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. *Annu Rev Immunol.* 2006; 24(1):705-738.
33. Rao SSP, Huntley MH, Durand NC, et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping [published correction appears in *Cell.* 2015;162(3):687-8]. *Cell.* 2014;159(7): 1665-1680.
34. Durand NC, Shamim MS, Machol I, et al. Juicer provides a one-click system for analyzing loop-resolution Hi-C experiments. *Cell Syst.* 2016;3(1):95-98.
35. Chen C, Yu W, Tober J, et al. Spatial genome re-organization between fetal and adult hematopoietic stem cells. *Cell Rep.* 2019;29(12):4200-4211.e7.
36. Dixon JR, Jung I, Selvaraj S, et al. Chromatin architecture reorganization during stem cell differentiation. *Nature.* 2015;518(7539): 331-336.
37. Schmitt AD, Hu M, Jung I, et al. A compendium of chromatin contact maps reveals spatially active regions in the human genome. *Cell Rep.* 2016;17(8):2042-2059.
38. Liu Y, Nanni L, Sungalee S, et al. Systematic inference and comparison of multi-scale chromatin sub-compartments connects spatial organization to cell phenotypes. *Nat Commun.* 2021;12(1):2439.
39. Wendorff AA, Quinn SA, Rashkovan M, et al. *Phf6* loss enhances HSC self-renewal driving tumor initiation and leukemia stem cell activity in T-ALL. *Cancer Discov.* 2019;9(3): 436-451.
40. Guo Y, Xu Q, Canzio D, et al. CRISPR inversion of CTCF sites alters genome topology and enhancer/promoter function. *Cell.* 2015;162(4):900-910.
41. León TE, Rapoz-D-Silva T, Bertoli C, et al. *EZH2*-deficient T-cell acute lymphoblastic leukemia is sensitized to CHK1 inhibition through enhanced replication stress. *Cancer Discov.* 2020;10(7):998-1017.
42. Chiaretti S, Li X, Gentleman R, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. *Blood.* 2004;103(7): 2771-2778.
43. Dunham I, Kundaje A, Aldred SF, et al; ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature.* 2012;489(7414): 57-74.
44. Lee W. A model to study the function of NPM-MLF1 in myelodysplasia [abstract]. *Blood.* 2010;116(21). Abstract 1571.
45. Li L, Leid M, Rothenberg EV. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. *Science.* 2010;329(5987):89-93.
46. Trinquand A, Dos Santos NR, Tran Quang C, et al. Triggering the TCR developmental checkpoint activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia. *Cancer Discov.* 2016;6(9): 972-985.
47. Belver L, Yang AY, Albero R, et al. GATA3-controlled nucleosome eviction drives MYC enhancer activity in T-cell development and leukemia. *Cancer Discov.* 2019; 9(12):1774-1791.
48. Kusakabe M, Sun AC, Tyshchenko K, et al. Synthetic modeling reveals HOXB genes are critical for the initiation and maintenance of human leukemia. *Nat Commun.* 2019;10(1): 2913.
49. Cobas M, Wilson A, Ernst B, et al. β -catenin is dispensable for hematopoiesis and lymphopoiesis. *J Exp Med.* 2004;199(2):221-229.
50. Jeannot G, Scheller M, Scarpellino L, et al. Long-term, multilineage hematopoiesis occurs in the combined absence of β -catenin and γ -catenin. *Blood.* 2008;111(1):142-149.
51. Koch U, Wilson A, Cobas M, Kemler R, Macdonald HR, Radtke F. Simultaneous loss of beta- and gamma-catenin does not perturb hematopoiesis or lymphopoiesis. *Blood.* 2008;111(1):160-164.
52. Graf T, Enver T. Forcing cells to change lineages. *Nature.* 2009;462(7273):587-594.
53. Ha VL, Luong A, Li F, et al. The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation. *Leukemia.* 2017;31(11): 2503-2514.
54. Sivakumar A, de Las Heras JI, Schirmer EC. Spatial genome organization: from development to disease. *Front Cell Dev Biol.* 2019;7:18.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.